Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1984 1
1986 2
1987 1
1988 6
1989 2
1990 4
1991 5
1992 7
1993 4
1994 8
1995 10
1996 13
1997 15
1998 14
1999 18
2000 36
2001 42
2002 36
2003 36
2004 45
2005 60
2006 94
2007 93
2008 125
2009 123
2010 152
2011 205
2012 196
2013 216
2014 266
2015 235
2016 251
2017 292
2018 306
2019 294
2020 319
2021 400
2022 342
2023 331
2024 107

Text availability

Article attribute

Article type

Publication date

Search Results

4,176 results

Results by year

Filters applied: . Clear all
Page 1
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.
Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, Muñoz-Sanjuan I, Sampaio C, Rosser AE, Leavitt BR. Tabrizi SJ, et al. Lancet Neurol. 2022 Jul;21(7):645-658. doi: 10.1016/S1474-4422(22)00121-1. Lancet Neurol. 2022. PMID: 35716694 Free PMC article. Review.
Huntington's disease is the most frequent autosomal dominant neurodegenerative disorder; however, no disease-modifying interventions are available for patients with this disease. ...Potential interventions for Huntington's disea
Huntington's disease is the most frequent autosomal dominant neurodegenerative disorder; however, no disease-mod
New Avenues for the Treatment of Huntington's Disease.
Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo PS, Rosenstock TR, Gil-Mohapel J. Kim A, et al. Int J Mol Sci. 2021 Aug 4;22(16):8363. doi: 10.3390/ijms22168363. Int J Mol Sci. 2021. PMID: 34445070 Free PMC article. Review.
Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG expansion in the HD gene. The disease is characterized by neurodegeneration, particularly in the striatum and cortex. ...
Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG expansion in the HD gene. The disease
Huntington's disease: a clinical review.
McColgan P, Tabrizi SJ. McColgan P, et al. Eur J Neurol. 2018 Jan;25(1):24-34. doi: 10.1111/ene.13413. Epub 2017 Sep 22. Eur J Neurol. 2018. PMID: 28817209 Review.
Huntington's disease (HD) is a fully penetrant neurodegenerative disease caused by a dominantly inherited CAG trinucleotide repeat expansion in the huntingtin gene on chromosome 4. ...In recent years there have been significant advances in understandin
Huntington's disease (HD) is a fully penetrant neurodegenerative disease caused by a dominantly inherited CAG tr
Gene targeting techniques for Huntington's disease.
Fields E, Vaughan E, Tripu D, Lim I, Shrout K, Conway J, Salib N, Lee Y, Dhamsania A, Jacobsen M, Woo A, Xue H, Cao K. Fields E, et al. Ageing Res Rev. 2021 Sep;70:101385. doi: 10.1016/j.arr.2021.101385. Epub 2021 Jun 5. Ageing Res Rev. 2021. PMID: 34098113 Free PMC article. Review.
Huntington's disease (HD) is an autosomal neurodegenerative disorder caused by extended trinucleotide CAG repetition in the HTT gene. ...Additionally, this review discusses a potential application of recent CRISPR prime editing technology in targeting
Huntington's disease (HD) is an autosomal neurodegenerative disorder caused by extended trinucleotide CAG repetition in
Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.
Tabrizi SJ, Ghosh R, Leavitt BR. Tabrizi SJ, et al. Neuron. 2019 Mar 6;101(5):801-819. doi: 10.1016/j.neuron.2019.01.039. Neuron. 2019. PMID: 30844400 Free article. Review.
Huntington's disease is caused by an abnormally expanded CAG repeat expansion in the HTT gene, which confers a predominant toxic gain of function in the mutant huntingtin (mHTT) protein. ...Improvements in the delivery and distribution of such agents as well
Huntington's disease is caused by an abnormally expanded CAG repeat expansion in the HTT gene, which confers a predomin
Clinical Features of Huntington's Disease.
Ghosh R, Tabrizi SJ. Ghosh R, et al. Adv Exp Med Biol. 2018;1049:1-28. doi: 10.1007/978-3-319-71779-1_1. Adv Exp Med Biol. 2018. PMID: 29427096 Review.
Huntington's disease (HD) is the most common monogenic neurodegenerative disease and the commonest genetic dementia in the developed world. ...Recent developments in therapeutics research, including gene silencing and targeted small molecule app
Huntington's disease (HD) is the most common monogenic neurodegenerative disease and the commonest genetic demen
Huntington's disease.
Ha AD, Fung VS. Ha AD, et al. Curr Opin Neurol. 2012 Aug;25(4):491-8. doi: 10.1097/WCO.0b013e3283550c97. Curr Opin Neurol. 2012. PMID: 22772878 Review.
PURPOSE OF REVIEW: This review highlights the recent advances in Huntington's disease, with particular focus on clinical characterization of prodromal Huntington's disease, as well as the growing literature regarding pathophysiological me …
PURPOSE OF REVIEW: This review highlights the recent advances in Huntington's disease, with particular focus on clinica …
Huntington's disease: from molecular pathogenesis to clinical treatment.
Ross CA, Tabrizi SJ. Ross CA, et al. Lancet Neurol. 2011 Jan;10(1):83-98. doi: 10.1016/S1474-4422(10)70245-3. Lancet Neurol. 2011. PMID: 21163446 Review.
Huntington's disease has served as a model for the study of other more common neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. ...Pathogenic pathways of Huntington's disease are beginning to
Huntington's disease has served as a model for the study of other more common neurodegenerative disorders, such as Alzh
Huntington's Disease: New Frontiers in Therapeutics.
Pan L, Feigin A. Pan L, et al. Curr Neurol Neurosci Rep. 2021 Feb 14;21(3):10. doi: 10.1007/s11910-021-01093-3. Curr Neurol Neurosci Rep. 2021. PMID: 33586075 Review.
PURPOSE OF REVIEW: This article describes and discusses new potential disease-modifying therapies for Huntington's disease that are currently in human clinical trials as well as promising new therapies in preclinical development. ...The etiology of …
PURPOSE OF REVIEW: This article describes and discusses new potential disease-modifying therapies for Huntington's d
A biological classification of Huntington's disease: the Integrated Staging System.
Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, Mestre TA, Panagoulias J, Ross CA, Zauderer M, Mullin AP, Romero K, Sivakumaran S, Turner EC, Long JD, Sampaio C; Huntington's Disease Regulatory Science Consortium (HD-RSC). Tabrizi SJ, et al. Lancet Neurol. 2022 Jul;21(7):632-644. doi: 10.1016/S1474-4422(22)00120-X. Lancet Neurol. 2022. PMID: 35716693 Review.
The HD-ISS characterises individuals for research purposes from birth, starting at Stage 0 (ie, individuals with the Huntington's disease genetic mutation without any detectable pathological change) by using a genetic definition of Huntington's
The HD-ISS characterises individuals for research purposes from birth, starting at Stage 0 (ie, individuals with the Huntington's
4,176 results